Adaptive alternative splicing correlates with less environmental risk of parkinsonism

Neurodegenerative Diseases

Volumn 9, Issue 2, 2012, Pages 87-98

  Benmoyal Segal, Liat ^a   Soreq, Lilach ^a   Ben Shaul, Yoram ^a   Ben Ari, Shani ^a   Ben Moshe, Tehila ^b   Aviel, Sigal ^b   Bergman, Hagai ^a   Soreq, Hermona ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b Protalix Biotherapeutics   (Israel)

Author keywords

Acetylcholinesterase; Alternative splicing; Animal models; Brain; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ACETYLCHOLINESTERASE; ENZYME VARIANT; RECOMBINANT ENZYME; SERINE ARGININE RICH PROTEIN; TRANSCRIPTOME;

ALTERNATIVE RNA SPLICING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; HYDROLYSIS; MOUSE; NONHUMAN; PARKINSONISM; PREFRONTAL CORTEX; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ACETYLCHOLINESTERASE; ADAPTATION, BIOLOGICAL; ALTERNATIVE SPLICING; ANIMALS; CLUSTER ANALYSIS; ENVIRONMENTAL EXPOSURE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; ISOENZYMES; MICE; MICE, TRANSGENIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARKINSONIAN DISORDERS; REAL-TIME POLYMERASE CHAIN REACTION; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 84856730233     PISSN: 16602854     EISSN: 16602862     Source Type: Journal    
DOI: 10.1159/000331328     Document Type: Article

References (41)

1. Xu Q, Modrek B, Lee C: Genome-wide detection of tissue-specific alternative splicing in the human transcriptome. Nucleic Acids Res 2002; 30: 3754-3766. (Pubitemid 35012448)
2. Stamm S, Ben-Ari S, Rafalska I, Tang Y, Zhang Z, Toiber D, Thanaraj TA, Soreq H: Function of alternative splicing. Gene 2005; 344: 1-20. (Pubitemid 40126788)
3. Schwerk C, Schulze-Osthoff K: Regulation of apoptosis by alternative pre-mRNA splicing. Mol Cell 2005; 19: 1-13. (Pubitemid 40884653)
4. Smith MJ, Sharples RA, Evin G, McLean CA, Dean B, Pavey G, Fantino E, Cotton RG, Imaizumi K, Masters CL, Cappai R, Culvenor JG: Expression of truncated presenilin 2 splice variant in Alzheimer's disease, bipolar disorder, and schizophrenia brain cortex. Brain Res Mol Brain Res 2004; 127: 128-135. (Pubitemid 39078599)
5. Jiang Z, Cote J, Kwon JM, Goate AM, Wu JY: Aberrant splicing of tau pre-mRNA caused by intronic mutations associated with the inherited dementia frontotemporal dementia with parkinsonism linked to chromosome 17. Mol Cell Biol 2000; 20: 4036-4048. (Pubitemid 30314502)
6. Berke JD, Sgambato V, Zhu PP, Lavoie B, Vincent M, Krause M, Hyman SE: Dopamine and glutamate induce distinct striatal splice forms of Ania-6, an RNA polymerase II-associated cyclin. Neuron 2001; 32: 277-287. (Pubitemid 33030195)
7. Zhou FM, Wilson C, Dani JA: Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 2003; 9: 23-36. (Pubitemid 36139576)
8. Benmoyal-Segal L, Soreq H: Gene-environment interactions in sporadic Parkinson's disease. J Neurochem 2006; 97: 1740-1755. (Pubitemid 43873664)
9. Manthripragada AD, Costello S, Cockburn MG, Bronstein JM, Ritz B: Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease. Epidemiology 2010; 21: 87-94.
10. Friedman A, Kaufer D, Shemer J, Hendler I, Soreq H, Tur-Kaspa I: Pyridostigmine brain penetration under stress enhances neuronal excitability and induces early immediate transcriptional response. Nat Med 1996; 2: 1382-1385.
11. Kaufer D, Friedman A, Seidman S, Soreq H: Acute stress facilitates long-lasting changes in cholinergic gene expression. Nature 1998; 393: 373-377. (Pubitemid 28269711)
12. Benmoyal-Segal L, Vander T, Shifman S, Bryk B, Ebstein RP, Marcus EL, Stessman J, Darvasi A, Herishanu Y, Friedman A, Soreq H: Acetylcholinesterase/ paraoxonase interactions increase the risk of insecticide-induced Parkinson's disease. Faseb J 2005; 19: 452-454. (Pubitemid 40316547)
13. Ben-Shaul Y, Benmoyal-Segal L, Ben-Ari S, Bergman H, Soreq H: Adaptive acetylcholinesterase splicing patterns attenuate 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced parkinsonism in mice. Eur J Neurosci 2006; 23: 2915-2922. (Pubitemid 43882870)
14. Meshorer E, Soreq H: Virtues and woes of AChE alternative splicing in stress-related neuropathologies. Trends Neurosci 2006; 29: 216-224.
15. Dauer W, Przedborski S: Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909. (Pubitemid 37130207)
16. Zang LY, Misra HP: Inactivation of acetylcholinesterase by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride. Mol Cell Biochem 2003; 254: 131-136. (Pubitemid 37483748)
17. Zang LY, Misra HP: Inhibition of acetylcholinesterase by the neurotoxicant, 1-methyl-4-phenyl-2,3-dihydropyridinium ion. Arch Biochem Biophys 1996; 336: 147-150. (Pubitemid 26423760)
18. Dery KJ, Gusti V, Gaur S, Shively JE, Yen Y, Gaur RK: Alternative splicing as a therapeutic target for human diseases. Methods Mol Biol 2009; 555: 127-144.
19. Ben-Shaul Y, Bergman H, Soreq H: Identifying subtle interrelated changes in functional gene categories using continuous measures of gene expression. Bioinformatics 2005; 21: 1129-1137. (Pubitemid 40467937)
20. Meshorer E, Bryk B, Toiber D, Cohen J, Podoly E, Dori A, Soreq H: SC35 promotes sustainable stress-induced alternative splicing of neuronal acetylcholinesterase mRNA. Mol Psychiatry 2005; 10: 985-997. (Pubitemid 41541984)
21. Affymetrix: Change algorithm. www.affymetrix. com.
22. Gu G, Deutch AY, Franklin J, Levy S, Wallace DC, Zhang J: Profiling genes related to mitochondrial function in mice treated with Nmethyl-4-phenyl-1,2,3, 6-tetrahydropyridine. Biochem Biophys Res Commun 2003; 308: 197-205. (Pubitemid 36904141)
23. Mandel S, Grunblatt E, Youdim M: cDNA microarray to study gene expression of dopaminergic neurodegeneration and neuroprotection in MPTP and 6-hydroxydopamine models: implications for idiopathic Parkinson's disease. J Neural Transm Suppl 2000; 60: 117-124. (Pubitemid 32037188)
24. Miller RM, Callahan LM, Casaceli C, Chen L, Kiser GL, Chui B, Kaysser-Kranich TM, Sendera TJ, Palaniappan C, Federoff HJ: Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned mouse substantia nigra. J Neurosci 2004; 24: 7445-7454. (Pubitemid 39166735)
25. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Church DM, DiCuccio M, Edgar R, Federhen S, Helmberg W, Kenton DL, Khovayko O, Lipman DJ, Madden TL, Maglott DR, Ostell J, Pontius JU, Pruitt KD, Schuler GD, Schriml LM, Sequeira E, Sherry ST, Sirotkin K, Starchenko G, Suzek TO, Tatusov R, Tatusova TA, Wagner L, Yaschenko E: Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 2005; 33:D39-D45. (Pubitemid 40207828)
26. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000; 25: 25-29. (Pubitemid 30257031)
27. Black DL: Mechanisms of alternative premessenger RNA splicing. Annu Rev Biochem 2003; 72: 291-336. (Pubitemid 36930448)
28. Long JC, Caceres JF: The SR protein family of splicing factors: master regulators of gene expression. Biochem J 2009; 417: 15-27.
29. Shaked I, Meerson A, Wolf Y, Avni R, Greenberg D, Gilboa-Geffen A, Soreq H: Micro RNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity 2009; 31: 965-973.
30. Sternfeld M, Shoham S, Klein O, Flores-Flores C, Evron T, Idelson GH, Kitsberg D, Patrick JW, Soreq H: Excess 'read-through' acetylcholinesterase attenuates but the 'synaptic' variant intensifies neurodeterioration correlates. Proc Natl Acad Sci USA 2000; 97: 8647-8652. (Pubitemid 30639727)
31. Podoly E, Hanin G, Soreq H: Alanine-tothreonine substitutions and amyloid diseases: Butyrylcholinesterase as a case study. Chem Biol Interact 2010; 187: 64-71.
32. D'Souza I, Schellenberg GD: Regulation of tau isoform expression and dementia. Biochim Biophys Acta 2005; 1739: 104-115. (Pubitemid 40021805)
33. Hatano T, Kubo S, Sato S, Hattori N: Pathogenesis of familial Parkinson's disease: new insights based on monogenic forms of Parkinson's disease. J Neurochem 2009; 111: 1075-1093.
34. Elbaz A, Clavel J, Rathouz PJ, Moisan F, Galanaud JP, Delemotte B, Alperovitch A, Tzourio C: Professional exposure to pesticides and Parkinson disease. Ann Neurol 2009; 66: 494-504.
35. Metz GA: Stress as a modulator of motor system function and pathology. Rev Neurosci 2007; 18: 209-222.
36. Goldman SM, Tanner CM, Oakes D, Bhudhikanok GS, Gupta A, Langston JW: Head injury and Parkinson's disease risk in twins. Ann Neurol 2006; 60: 65-72.
37. Lee JK, Tran T, Tansey MG: Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol 2009; 4: 419-429.
38. Darreh-Shori T, Hellstrom-Lindahl E, Flores-Flores C, Guan ZZ, Soreq H, Nordberg A: Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients. J Neurochem 2004; 88: 1102-1113. (Pubitemid 38280678)
39. Berson A, Knobloch M, Hanan M, Diamant S, Sharoni M, Schuppli D, Geyer BC, Ravid R, Mor TS, Nitsch RM, Soreq H: Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology. Brain 2008; 131: 109-119.
40. Opalinska JB, Gewirtz AM: Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 2002; 1: 503-514. (Pubitemid 37361504)
41. Inc P, 2008. Partek Discovery SuiteTM Partek Inc., St. Louis.